BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 24008667)

  • 1. hr-HPV testing in the follow-up of women with cytological abnormalities and negative colposcopy.
    Carozzi F; Visioli CB; Confortini M; Iossa A; Mantellini P; Burroni E; Zappa M
    Br J Cancer; 2013 Oct; 109(7):1766-74. PubMed ID: 24008667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program.
    Lazcano-Ponce E; Lörincz AT; Salmerón J; Fernández I; Cruz A; Hernández P; Mejia I; Hernández-Avila M
    Cancer Causes Control; 2010 Oct; 21(10):1693-700. PubMed ID: 20617376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
    Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
    Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
    Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
    BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology-Results from the Hammersmith study.
    Cuzick J; Szarewski A; Mesher D; Cadman L; Austin J; Perryman K; Ho L; Terry G; Sasieni P; Dina R; Soutter WP
    Int J Cancer; 2008 May; 122(10):2294-300. PubMed ID: 18240149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation.
    Verguts J; Bronselaer B; Donders G; Arbyn M; Van Eldere J; Drijkoningen M; Poppe W
    BJOG; 2006 Nov; 113(11):1303-7. PubMed ID: 16978225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human papillomavirus testing improves the accuracy of colposcopy in detection of cervical intraepithelial neoplasia.
    Monsonego J; Pintos J; Semaille C; Beumont M; Dachez R; Zerat L; Bianchi A; Franco E
    Int J Gynecol Cancer; 2006; 16(2):591-8. PubMed ID: 16681731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immediate histopathologic follow-up of cervista and aptima high-risk HPV assays in women with LSIL cytology.
    Zhang H; Varma KR; Han M; Matsko J; Zhao C
    Cancer Cytopathol; 2018 Aug; 126(8):525-532. PubMed ID: 29797678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico.
    Salmerón J; Lazcano-Ponce E; Lorincz A; Hernández M; Hernández P; Leyva A; Uribe M; Manzanares H; Antunez A; Carmona E; Ronnett BM; Sherman ME; Bishai D; Ferris D; Flores Y; Yunes E; Shah KV
    Cancer Causes Control; 2003 Aug; 14(6):505-12. PubMed ID: 12948281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human papillomavirus (HPV) testing in the management of women with abnormal Pap smears. Experience of a colposcopy referral clinic.
    Ciotti M; Sesti F; Paba P; Benedetto A; Patrizi L; Criscuolo A; Piccione E; Branca M; Syrjänen K; Favalli C
    Eur J Gynaecol Oncol; 2004; 25(5):577-84. PubMed ID: 15493169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain.
    Ibáñez R; Moreno-Crespi J; Sardà M; Autonell J; Fibla M; Gutiérrez C; Lloveras B; Alejo M; Català I; Alameda F; Casas M; Bosch FX; de Sanjosé S
    BMC Infect Dis; 2012 Jan; 12():25. PubMed ID: 22280073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
    Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
    JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results.
    Manos MM; Kinney WK; Hurley LB; Sherman ME; Shieh-Ngai J; Kurman RJ; Ransley JE; Fetterman BJ; Hartinger JS; McIntosh KM; Pawlick GF; Hiatt RA
    JAMA; 1999 May; 281(17):1605-10. PubMed ID: 10235153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-risk HPV detection and associated cervical lesions in a population of French menopausal women.
    Tifaoui N; Maudelonde T; Combecal J; Vallo R; Doutre S; Didelot MN; Nagot N; Segondy M; Boulle N
    J Clin Virol; 2018 Nov; 108():12-18. PubMed ID: 30196012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.
    Arbyn M; Roelens J; Simoens C; Buntinx F; Paraskevaidis E; Martin-Hirsch PP; Prendiville WJ
    Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD008054. PubMed ID: 23543559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.
    Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Gillio-Tos A; Minucci D; Naldoni C; Rizzolo R; Schincaglia P; Volante R; Zappa M; Zorzi M; Cuzick J; Segnan N;
    J Natl Cancer Inst; 2008 Apr; 100(7):492-501. PubMed ID: 18364502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
    Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
    J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPV testing with cytology triage for cervical cancer screening in routine practice.
    Louvanto K; Chevarie-Davis M; Ramanakumar AV; Franco EL; Ferenczy A
    Am J Obstet Gynecol; 2014 May; 210(5):474.e1-7. PubMed ID: 24373948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.